Literature DB >> 34863779

Modeling Innate Antiviral Immunity in Physiological Context.

Monty E Goldstein1, Margaret A Scull2.   

Abstract

An effective innate antiviral response is critical for the mitigation of severe disease and host survival following infection. In vivo, the innate antiviral response is triggered by cells that detect the invading pathogen and then communicate through autocrine and paracrine signaling to stimulate the expression of genes that inhibit viral replication, curtail cell proliferation, or modulate the immune response. In other words, the innate antiviral response is complex and dynamic. Notably, in the laboratory, culturing viruses and assaying viral life cycles frequently utilizes cells that are derived from tissues other than those that support viral replication during natural infection, while the study of viral pathogenesis often employs animal models. In recapitulating the human antiviral response, it is important to consider that variation in the expression and function of innate immune sensors and antiviral effectors exists across species, cell types, and cell differentiation states, as well as when cells are placed in different contexts. Thus, to gain novel insight into the dynamics of the host response and how specific sensors and effectors impact infection kinetics by a particular virus, the model system must be selected carefully. In this review, we briefly introduce key signaling pathways involved in the innate antiviral response and highlight how these differ between systems. We then review the application of tissue-engineered or 3D models for studying the antiviral response, and suggest how these in vitro culture systems could be further utilized to assay physiologically-relevant host responses and reveal novel insight into virus-host interactions.
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  interferon; microenvironment; organoids; pattern recognition receptors; tissue engineering

Mesh:

Year:  2021        PMID: 34863779      PMCID: PMC8940657          DOI: 10.1016/j.jmb.2021.167374

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  222 in total

Review 1.  From evolutionary genetics to human immunology: how selection shapes host defence genes.

Authors:  Luis B Barreiro; Lluís Quintana-Murci
Journal:  Nat Rev Genet       Date:  2009-12-01       Impact factor: 53.242

2.  TLR13 recognizes bacterial 23S rRNA devoid of erythromycin resistance-forming modification.

Authors:  Marina Oldenburg; Anne Krüger; Ruth Ferstl; Andreas Kaufmann; Gernot Nees; Anna Sigmund; Barbara Bathke; Henning Lauterbach; Mark Suter; Stefan Dreher; Uwe Koedel; Shizuo Akira; Taro Kawai; Jan Buer; Hermann Wagner; Stefan Bauer; Hubertus Hochrein; Carsten J Kirschning
Journal:  Science       Date:  2012-07-19       Impact factor: 47.728

3.  Laminar flow attenuates interferon-induced inflammatory responses in endothelial cells.

Authors:  Yu-Chih Tsai; Hsyue-Jen Hsieh; Fang Liao; Chih-Wen Ni; Yuen-Jen Chao; Chung-Yu Hsieh; Danny Ling Wang
Journal:  Cardiovasc Res       Date:  2007-03-02       Impact factor: 10.787

4.  Modeling of Fibrotic Lung Disease Using 3D Organoids Derived from Human Pluripotent Stem Cells.

Authors:  Alexandros Strikoudis; Anna Cieślak; Lucas Loffredo; Ya-Wen Chen; Nina Patel; Anjali Saqi; David J Lederer; Hans-Willem Snoeck
Journal:  Cell Rep       Date:  2019-06-18       Impact factor: 9.423

5.  Mode of transmission affects the sensitivity of human immunodeficiency virus type 1 to restriction by rhesus TRIM5alpha.

Authors:  Max W Richardson; Richard G Carroll; Matthew Stremlau; Nikolay Korokhov; Laurent M Humeau; Guido Silvestri; Joseph Sodroski; James L Riley
Journal:  J Virol       Date:  2008-09-03       Impact factor: 5.103

6.  Impaired interferon signaling is a common immune defect in human cancer.

Authors:  Rebecca J Critchley-Thorne; Diana L Simons; Ning Yan; Andrea K Miyahira; Frederick M Dirbas; Denise L Johnson; Susan M Swetter; Robert W Carlson; George A Fisher; Albert Koong; Susan Holmes; Peter P Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-18       Impact factor: 11.205

7.  Characterization of the type I interferon locus and identification of novel genes.

Authors:  Matthew P Hardy; Catherine M Owczarek; Lars S Jermiin; Mikael Ejdebäck; Paul J Hertzog
Journal:  Genomics       Date:  2004-08       Impact factor: 5.736

8.  p53 down-regulates SARS coronavirus replication and is targeted by the SARS-unique domain and PLpro via E3 ubiquitin ligase RCHY1.

Authors:  Yue Ma-Lauer; Javier Carbajo-Lozoya; Marco Y Hein; Marcel A Müller; Wen Deng; Jian Lei; Benjamin Meyer; Yuri Kusov; Brigitte von Brunn; Dev Raj Bairad; Sabine Hünten; Christian Drosten; Heiko Hermeking; Heinrich Leonhardt; Matthias Mann; Rolf Hilgenfeld; Albrecht von Brunn
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-12       Impact factor: 11.205

Review 9.  Advancing lung organoids for COVID-19 research.

Authors:  Jelte van der Vaart; Mart M Lamers; Bart L Haagmans; Hans Clevers
Journal:  Dis Model Mech       Date:  2021-06-28       Impact factor: 5.758

10.  TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines.

Authors:  Min Zheng; Rajendra Karki; Evan Peter Williams; Dong Yang; Elizabeth Fitzpatrick; Peter Vogel; Colleen Beth Jonsson; Thirumala-Devi Kanneganti
Journal:  Nat Immunol       Date:  2021-05-07       Impact factor: 25.606

View more
  2 in total

Review 1.  Engineering complexity in human tissue models of cancer.

Authors:  Kacey Ronaldson-Bouchard; Ilaria Baldassarri; Daniel Naveed Tavakol; Pamela L Graney; Maria Samaritano; Elisa Cimetta; Gordana Vunjak-Novakovic
Journal:  Adv Drug Deliv Rev       Date:  2022-03-09       Impact factor: 17.873

Review 2.  Bacterial-Viral Interactions in Human Orodigestive and Female Genital Tract Cancers: A Summary of Epidemiologic and Laboratory Evidence.

Authors:  Ikuko Kato; Jilei Zhang; Jun Sun
Journal:  Cancers (Basel)       Date:  2022-01-15       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.